Clinical Trials Logo

HER2-positive Solid Tumor clinical trials

View clinical trials related to HER2-positive Solid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05523947 Recruiting - Clinical trials for HER2-Positive Solid Tumor

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Start date: August 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.

NCT ID: NCT04757090 Withdrawn - Clinical trials for HER2-positive Solid Tumor

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Start date: December 31, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111

NCT ID: NCT04040699 Completed - Clinical trials for HER2 Positive Solid Tumor

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Start date: September 26, 2019
Phase: Phase 1
Study type: Interventional

This is a phase Ib, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN026 combined with KN046 in subjects with advanced HER2 positive solid tumors.

NCT ID: NCT03650348 Completed - Clinical trials for HER2-positive Breast Cancer

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Start date: August 21, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.

NCT ID: NCT03330561 Completed - Clinical trials for HER2-positive Breast Cancer

PRS-343 in HER2-Positive Solid Tumors

Start date: September 13, 2017
Phase: Phase 1
Study type: Interventional

A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.